PIKfyve controls dendritic cell function and tumor immunity
The modern armamentarium for cancer treatment includes immunotherapy and targeted therapy, such as protein kinase inhibitors. However, the mechanisms that allow cancer-targeting drugs to effectively mobilize dendritic cells (DCs) and affect immunotherapy are poorly understood. Here, we report that among shared gene targets of clinically relevant protein kinase inhibitors, high PIKFYVE expression was least predictive of complete response in patients who received immune checkpoint blockade (ICB). In immune cells, high PIKFYVE expression in DCs was associated with worse response to ICB. Genetic and pharmacological studies demonstrated that PIKfyve ablation enhanced DC function via selectively altering the alternate/non-canonical NF-κB pathway. Both loss of Pikfyve in DCs and treatment with apilimod, a potent and specific PIKfyve inhibitor, restrained tumor growth, enhanced DC-dependent T cell immunity, and potentiated ICB efficacy in tumor-bearing mouse models. Furthermore, the combination of a vaccine adjuvant and apilimod reduced tumor progression in vivo. Thus, PIKfyve negatively controls DCs, and PIKfyve inhibition has promise for cancer immunotherapy and vaccine treatment strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2024) vom: 02. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Jae Eun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigen-specific T cell |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2024.02.28.582543 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369539842 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369539842 | ||
| 003 | DE-627 | ||
| 005 | 20240322000525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.02.28.582543 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369539842 | ||
| 035 | |a (NLM)38464258 | ||
| 035 | |a (PII)2024.02.28.582543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Jae Eun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PIKfyve controls dendritic cell function and tumor immunity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The modern armamentarium for cancer treatment includes immunotherapy and targeted therapy, such as protein kinase inhibitors. However, the mechanisms that allow cancer-targeting drugs to effectively mobilize dendritic cells (DCs) and affect immunotherapy are poorly understood. Here, we report that among shared gene targets of clinically relevant protein kinase inhibitors, high PIKFYVE expression was least predictive of complete response in patients who received immune checkpoint blockade (ICB). In immune cells, high PIKFYVE expression in DCs was associated with worse response to ICB. Genetic and pharmacological studies demonstrated that PIKfyve ablation enhanced DC function via selectively altering the alternate/non-canonical NF-κB pathway. Both loss of Pikfyve in DCs and treatment with apilimod, a potent and specific PIKfyve inhibitor, restrained tumor growth, enhanced DC-dependent T cell immunity, and potentiated ICB efficacy in tumor-bearing mouse models. Furthermore, the combination of a vaccine adjuvant and apilimod reduced tumor progression in vivo. Thus, PIKfyve negatively controls DCs, and PIKfyve inhibition has promise for cancer immunotherapy and vaccine treatment strategies | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a NF-κB | |
| 650 | 4 | |a PIKfyve | |
| 650 | 4 | |a antigen-specific T cell | |
| 650 | 4 | |a apilimod | |
| 650 | 4 | |a cancer vaccine | |
| 650 | 4 | |a dendritic cell | |
| 650 | 4 | |a immune checkpoint blockade | |
| 650 | 4 | |a kinase inhibitor | |
| 650 | 4 | |a tumor | |
| 700 | 1 | |a Qiao, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Kryczek, Ilona |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jiali |e verfasserin |4 aut | |
| 700 | 1 | |a Gurkan, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Gondal, Mahnoor |e verfasserin |4 aut | |
| 700 | 1 | |a Tien, Jean Ching-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Maj, Tomasz |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdani, Sahr |e verfasserin |4 aut | |
| 700 | 1 | |a Parolia, Abhijit |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Houjun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, JiaJia |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Grove, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Vatan, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Gaopeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuping |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Xuhong |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Fengyun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a He, Tongchen |e verfasserin |4 aut | |
| 700 | 1 | |a Cieslik, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Weiping |e verfasserin |4 aut | |
| 700 | 1 | |a Chinnaiyan, Arul M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2024) vom: 02. März |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.02.28.582543 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 03 | ||